Pulsatile plasma filtration and cell-free DNA amplification using a water-head-driven point-of-care testing chip

Lab on a Chip ◽  
2018 ◽  
Vol 18 (6) ◽  
pp. 915-922 ◽  
Author(s):  
Yonghun Lee ◽  
Dong-Min Kim ◽  
Zhenglin Li ◽  
Dong-Eun Kim ◽  
Sung-Jin Kim
Keyword(s):  
Blood Plasma ◽  
Point Of Care ◽  
Dna Amplification ◽  
Point Of Care Testing ◽  
Cell Free Dna ◽  
Free Dna ◽  
Water Head ◽  
Plasma Filtration ◽  
On Chip

This paper presents pulsatile blood-plasma filtration and on-chip amplification of cell-free DNA, which obviates the need for any dynamic external controllers for point-of-care testing.

Point-of-Care Systems for Rapid DNA Quantification in Oncology

2008 ◽  
Vol 94 (2) ◽  
pp. 216-225 ◽  
Author(s):  
Marco Bianchessi ◽  
Sarah Burgarella ◽  
Marco Cereda
Keyword(s):  
Point Of Care ◽  
Low Cost ◽  
Semiconductor Industry ◽  
Point Of Care Testing ◽  
Lab On Chip ◽  
Diagnostic Assays ◽  
Care Systems ◽  
Point Of Care Systems ◽  
The Common ◽  
On Chip

The development of new powerful applications and the improvement in fabrication techniques are promising an explosive growth in lab-on-chip use in the upcoming future. As the demand reaches significant levels, the semiconductor industry may enter in the field, bringing its capability to produce complex devices in large volumes, high quality and low cost. The lab-on-chip concept, when applied to medicine, leads to the point-of-care concept, where simple, compact and cheap instruments allow diagnostic assays to be performed quickly by untrained personnel directly at the patient's side. In this paper, some practical and economical considerations are made to support the advantages of point-of-care testing. A series of promising technologies developed by STMicroelectronics on lab-on-chips is also presented, mature enough to enter in the common medical practice. The possible use of these techniques for cancer research, diagnosis and treatment are illustrated together with the benefits offered by their implementation in point-of-care testing.

scholarly journals Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients

2017 ◽  
Vol 9 (1) ◽  
Author(s):  
Luka de Vos ◽  
Heidrun Gevensleben ◽  
Andreas Schröck ◽  
Alina Franzen ◽  
Glen Kristiansen ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Blood Plasma ◽  
Cancer Patients ◽  
Cell Free Dna ◽  
Free Dna ◽  
In Blood Plasma ◽  
Circulating Cell Free Dna

scholarly journals Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Inessa Skrypkina ◽  
Liudmyla Tsyba ◽  
Kateryna Onyshchenko ◽  
Dmytro Morderer ◽  
Olena Kashparova ◽  
...  
Keyword(s):  
Blood Plasma ◽  
Cancer Patients ◽  
Renal Cancer ◽  
Cpg Islands ◽  
Tumor Development ◽  
Diagnostic Markers ◽  
Cell Free Dna ◽  
Free Dna ◽  
Healthy Donors ◽  
Fluorescence Test

The critical point for successful treatment of cancer is diagnosis at early stages of tumor development. Cancer cell-specific methylated DNA has been found in the blood of cancer patients, indicating that cell-free DNA (cfDNA) circulating in the blood is a convenient tumor-associated DNA marker. Therefore methylated cfDNA can be used as a minimally invasive diagnostic marker. We analysed the concentration of plasma cfDNA and methylation of six tumor suppressor genes in samples of 27 patients with renal cancer and 15 healthy donors as controls. The cfDNA concentrations in samples from cancer patients and healthy donors was measured using two different methods, the SYBR Green I fluorescence test and quantitative real-time PCR. Both methods revealed a statistically significant increase of cfDNA concentrations in cancer patients. Hypermethylation on cfDNA was detected for theLRRC3B(74.1%),APC(51.9%),FHIT(55.6%), andRASSF1(62.9%) genes in patients with renal cancer. Promoter methylation ofVHLandITGA9genes was not found on cfDNA. Our results confirmed that the cfDNA level and methylation of CpG islands ofRASSF1A,FHIT, andAPCgenes in blood plasma can be used as noninvasive diagnostic markers of cancer.

scholarly journals Cell free DNA from respiratory pathogens is detectable in the blood plasma of Cystic Fibrosis patients

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Sara L. Rassoulian Barrett ◽  
Elizabeth A. Holmes ◽  
Dustin R. Long ◽  
Ryan C. Shean ◽  
Gilbert E. Bautista ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Blood Plasma ◽  
Respiratory Pathogens ◽  
Cell Free Dna ◽  
Free Dna

scholarly journals Circulating DNA, a Potentially Sensitive and Specific Diagnostic Tool for Future Medicine

Dose-Response ◽  
2019 ◽  
Vol 17 (4) ◽  
pp. 155932581989101
Author(s):  
Fan Jiang ◽  
Xiaoxiao Yang ◽  
Xiping He ◽  
Mingming Yang
Keyword(s):  
Early Stage ◽  
Point Of Care ◽  
Circulating Dna ◽  
Fetal Cell ◽  
Early Screening ◽  
Cell Free Dna ◽  
Promising Tool ◽  
Free Dna ◽  
Cancer Types ◽  
Commercial Kits

Liquid biopsy has the great potential of detecting early diseases before deterioration and is valued for screening abnormalities at early stage. In oncology, circulating DNA derived from shed cancer cells reflects the tissue of origin, so it could be used to locate tissue sites during early screening. However, the heterogenous parameters of different types limit the clinical application, making it inaccessible to encompass all the cancer types. Instead, for reproducible scenario as pregnancy, fetal cell-free DNA has been well utilized for screening aneuploidies. Noninvasive and convenient as is, it would be of great value in the next decades far more than early diagnosis. This review recapitulates the discovery and development of tumor and fetal cell-free DNA. The common factors are also present that could be taken into consideration when collecting, transporting, and preserving samples. Meanwhile, several protocols used for purifying cell-free DNA, either classic ones or through commercial kits, are compared carefully. In addition, the development of technologies for analyzing cell-free DNA have been summarized and discussed in detail, especially some up-to-date approaches. At the end, the potential prospect of circulating DNA is bravely depicted. In summary, although there would be a lot of efforts before it’s prevalent, cell-free DNA remains a promising tool in point-of-care diagnostic medicine.

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

10.3791/61449 ◽  
2020 ◽  
Author(s):  
Vikrant Palande ◽  
Dorith Raviv Shay ◽  
MILANA Frenkel-Morgenstern
Keyword(s):  
Blood Plasma ◽  
Cancer Patients ◽  
Plasma Samples ◽  
Cell Free Dna ◽  
Free Dna ◽  
In Blood Plasma
Sign in / Sign up

Export Citation Format

Share Document